Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma

Christopher J. Sweeney, Junming Zhu, Alan B. Sandler, Joan Schiller, Chandra P. Belani, Corey Langer, James Krook, David Harrington, David H. Johnson

Research output: Contribution to journalArticle

203 Citations (Scopus)

Abstract

BACKGROUND. Eastern Cooperative Oncology Group (ECOG) Study E1594 compared paclitaxel and cisplatin with three newer chemotherapy doublets in the treatment of patients with advanced nonsmall cell lung carcinoma (NSCLC). The accrual of patients with an ECOG performance status (PS) of 2 was discontinued due to a perceived rate of unacceptable toxicity. METHODS. Patients were stratified by PS and randomized to one of the following treatments: 1) paclitaxel (135 mg/m2) over 24 hours with cisplatin (75 mg/m2) on a 21-day cycle; 2) cisplatin (100 mg/m2) with gemcitabine (1 g/m2) on Days 1, 8, and 15 on a 28-day cycle; 3) cisplatin (75 mg/m2) with docetaxel (75 mg/m2) on a 21-day cycle; and 4) paclitaxel (225 mg/m2) over 3 hours with carboplatin (area under the curve, 6). All tests of statistical significance were two-sided. RESULTS. Sixty-eight patients with an ECOG PS of 2 were enrolled, and 64 patients were evaluable for toxicity and response. Fifty-six percent of 64 evaluable patients were male, and 81% had Stage IV disease. Grade 3-4 hematologic toxicities occurred in > 50% of the patients in each treatment group. Nonhematologic Grade 3-4 toxicities occurred significantly less often in the paclitaxel and carboplatin arm (P = 0.0032). The overall rate of toxicity did not differ significantly from the rate of toxicity in the PS-0 or PS-1 cohorts. There were 5 deaths (7.35%) among 68 patients with a PS of 2 during therapy; however, only 2 of those deaths were attributed to therapy. The overall response rate for the 64 evaluable patients was 14%. The overall median survival of all 68 patients with a PS of 2, as determined by an intent-to-treat analysis, was 4.1 months. CONCLUSIONS. Patients with advanced NSCLC and a PS of 2 experienced a large number of adverse reactions and overall poor survival. A comparison with patients with a PS of 0-1 suggests that these events and the shorter survival were related to disease process rather than treatment. Alternative strategies need to be explored with therapy specifically tailored for this group of patients.

Original languageEnglish (US)
Pages (from-to)2639-2647
Number of pages9
JournalCancer
Volume92
Issue number10
DOIs
StatePublished - Nov 15 2001

Fingerprint

Carcinoma
Lung
Paclitaxel
Cisplatin
Carboplatin
docetaxel
gemcitabine
Therapeutics
Survival
Area Under Curve
Drug Therapy

Keywords

  • Chemotherapy
  • Eastern Cooperative Oncology Group
  • Nonsmall cell lung carcinoma
  • Performance status 2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 : A phase III trial in patients with metastatic nonsmall cell lung carcinoma. / Sweeney, Christopher J.; Zhu, Junming; Sandler, Alan B.; Schiller, Joan; Belani, Chandra P.; Langer, Corey; Krook, James; Harrington, David; Johnson, David H.

In: Cancer, Vol. 92, No. 10, 15.11.2001, p. 2639-2647.

Research output: Contribution to journalArticle

Sweeney, Christopher J. ; Zhu, Junming ; Sandler, Alan B. ; Schiller, Joan ; Belani, Chandra P. ; Langer, Corey ; Krook, James ; Harrington, David ; Johnson, David H. / Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594 : A phase III trial in patients with metastatic nonsmall cell lung carcinoma. In: Cancer. 2001 ; Vol. 92, No. 10. pp. 2639-2647.
@article{a5488b612764444bac00eb0d95e72081,
title = "Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594: A phase III trial in patients with metastatic nonsmall cell lung carcinoma",
abstract = "BACKGROUND. Eastern Cooperative Oncology Group (ECOG) Study E1594 compared paclitaxel and cisplatin with three newer chemotherapy doublets in the treatment of patients with advanced nonsmall cell lung carcinoma (NSCLC). The accrual of patients with an ECOG performance status (PS) of 2 was discontinued due to a perceived rate of unacceptable toxicity. METHODS. Patients were stratified by PS and randomized to one of the following treatments: 1) paclitaxel (135 mg/m2) over 24 hours with cisplatin (75 mg/m2) on a 21-day cycle; 2) cisplatin (100 mg/m2) with gemcitabine (1 g/m2) on Days 1, 8, and 15 on a 28-day cycle; 3) cisplatin (75 mg/m2) with docetaxel (75 mg/m2) on a 21-day cycle; and 4) paclitaxel (225 mg/m2) over 3 hours with carboplatin (area under the curve, 6). All tests of statistical significance were two-sided. RESULTS. Sixty-eight patients with an ECOG PS of 2 were enrolled, and 64 patients were evaluable for toxicity and response. Fifty-six percent of 64 evaluable patients were male, and 81{\%} had Stage IV disease. Grade 3-4 hematologic toxicities occurred in > 50{\%} of the patients in each treatment group. Nonhematologic Grade 3-4 toxicities occurred significantly less often in the paclitaxel and carboplatin arm (P = 0.0032). The overall rate of toxicity did not differ significantly from the rate of toxicity in the PS-0 or PS-1 cohorts. There were 5 deaths (7.35{\%}) among 68 patients with a PS of 2 during therapy; however, only 2 of those deaths were attributed to therapy. The overall response rate for the 64 evaluable patients was 14{\%}. The overall median survival of all 68 patients with a PS of 2, as determined by an intent-to-treat analysis, was 4.1 months. CONCLUSIONS. Patients with advanced NSCLC and a PS of 2 experienced a large number of adverse reactions and overall poor survival. A comparison with patients with a PS of 0-1 suggests that these events and the shorter survival were related to disease process rather than treatment. Alternative strategies need to be explored with therapy specifically tailored for this group of patients.",
keywords = "Chemotherapy, Eastern Cooperative Oncology Group, Nonsmall cell lung carcinoma, Performance status 2",
author = "Sweeney, {Christopher J.} and Junming Zhu and Sandler, {Alan B.} and Joan Schiller and Belani, {Chandra P.} and Corey Langer and James Krook and David Harrington and Johnson, {David H.}",
year = "2001",
month = "11",
day = "15",
doi = "10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8",
language = "English (US)",
volume = "92",
pages = "2639--2647",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "10",

}

TY - JOUR

T1 - Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594

T2 - A phase III trial in patients with metastatic nonsmall cell lung carcinoma

AU - Sweeney, Christopher J.

AU - Zhu, Junming

AU - Sandler, Alan B.

AU - Schiller, Joan

AU - Belani, Chandra P.

AU - Langer, Corey

AU - Krook, James

AU - Harrington, David

AU - Johnson, David H.

PY - 2001/11/15

Y1 - 2001/11/15

N2 - BACKGROUND. Eastern Cooperative Oncology Group (ECOG) Study E1594 compared paclitaxel and cisplatin with three newer chemotherapy doublets in the treatment of patients with advanced nonsmall cell lung carcinoma (NSCLC). The accrual of patients with an ECOG performance status (PS) of 2 was discontinued due to a perceived rate of unacceptable toxicity. METHODS. Patients were stratified by PS and randomized to one of the following treatments: 1) paclitaxel (135 mg/m2) over 24 hours with cisplatin (75 mg/m2) on a 21-day cycle; 2) cisplatin (100 mg/m2) with gemcitabine (1 g/m2) on Days 1, 8, and 15 on a 28-day cycle; 3) cisplatin (75 mg/m2) with docetaxel (75 mg/m2) on a 21-day cycle; and 4) paclitaxel (225 mg/m2) over 3 hours with carboplatin (area under the curve, 6). All tests of statistical significance were two-sided. RESULTS. Sixty-eight patients with an ECOG PS of 2 were enrolled, and 64 patients were evaluable for toxicity and response. Fifty-six percent of 64 evaluable patients were male, and 81% had Stage IV disease. Grade 3-4 hematologic toxicities occurred in > 50% of the patients in each treatment group. Nonhematologic Grade 3-4 toxicities occurred significantly less often in the paclitaxel and carboplatin arm (P = 0.0032). The overall rate of toxicity did not differ significantly from the rate of toxicity in the PS-0 or PS-1 cohorts. There were 5 deaths (7.35%) among 68 patients with a PS of 2 during therapy; however, only 2 of those deaths were attributed to therapy. The overall response rate for the 64 evaluable patients was 14%. The overall median survival of all 68 patients with a PS of 2, as determined by an intent-to-treat analysis, was 4.1 months. CONCLUSIONS. Patients with advanced NSCLC and a PS of 2 experienced a large number of adverse reactions and overall poor survival. A comparison with patients with a PS of 0-1 suggests that these events and the shorter survival were related to disease process rather than treatment. Alternative strategies need to be explored with therapy specifically tailored for this group of patients.

AB - BACKGROUND. Eastern Cooperative Oncology Group (ECOG) Study E1594 compared paclitaxel and cisplatin with three newer chemotherapy doublets in the treatment of patients with advanced nonsmall cell lung carcinoma (NSCLC). The accrual of patients with an ECOG performance status (PS) of 2 was discontinued due to a perceived rate of unacceptable toxicity. METHODS. Patients were stratified by PS and randomized to one of the following treatments: 1) paclitaxel (135 mg/m2) over 24 hours with cisplatin (75 mg/m2) on a 21-day cycle; 2) cisplatin (100 mg/m2) with gemcitabine (1 g/m2) on Days 1, 8, and 15 on a 28-day cycle; 3) cisplatin (75 mg/m2) with docetaxel (75 mg/m2) on a 21-day cycle; and 4) paclitaxel (225 mg/m2) over 3 hours with carboplatin (area under the curve, 6). All tests of statistical significance were two-sided. RESULTS. Sixty-eight patients with an ECOG PS of 2 were enrolled, and 64 patients were evaluable for toxicity and response. Fifty-six percent of 64 evaluable patients were male, and 81% had Stage IV disease. Grade 3-4 hematologic toxicities occurred in > 50% of the patients in each treatment group. Nonhematologic Grade 3-4 toxicities occurred significantly less often in the paclitaxel and carboplatin arm (P = 0.0032). The overall rate of toxicity did not differ significantly from the rate of toxicity in the PS-0 or PS-1 cohorts. There were 5 deaths (7.35%) among 68 patients with a PS of 2 during therapy; however, only 2 of those deaths were attributed to therapy. The overall response rate for the 64 evaluable patients was 14%. The overall median survival of all 68 patients with a PS of 2, as determined by an intent-to-treat analysis, was 4.1 months. CONCLUSIONS. Patients with advanced NSCLC and a PS of 2 experienced a large number of adverse reactions and overall poor survival. A comparison with patients with a PS of 0-1 suggests that these events and the shorter survival were related to disease process rather than treatment. Alternative strategies need to be explored with therapy specifically tailored for this group of patients.

KW - Chemotherapy

KW - Eastern Cooperative Oncology Group

KW - Nonsmall cell lung carcinoma

KW - Performance status 2

UR - http://www.scopus.com/inward/record.url?scp=0035889915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035889915&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8

DO - 10.1002/1097-0142(20011115)92:10<2639::AID-CNCR1617>3.0.CO;2-8

M3 - Article

C2 - 11745199

AN - SCOPUS:0035889915

VL - 92

SP - 2639

EP - 2647

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -